The cancer therapy developer boosted a series B round led by Novo and backed by Celgene to $75.2m, with both corporates contributing to the latest tranche.

US-based synthetic cancer drug developer Cyteir Therapeutics increased a series B round led by pharmaceutical firm Novo to $75.2m yesterday. The company added $40.2m to close the round, which included pharmaceutical company Celgene, Osage University Partners (OUP), Droia Oncology Ventures, Lightstone Ventures and Venrock. The latter three had provided the round’s $29m first tranche in…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.